Selected research
Industry Research
Fibromyalgia Therapeutics Drugs Industry Research Report 2026
Market perspective
The global Fibromyalgia Therapeutics Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fibromyalgia Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fibromyalgia Therapeutics Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fibromyalgia Therapeutics Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fibromyalgia Therapeutics Drugs include Eli Lilly, Pfizer, Zynerba Pharmaceuticals, Tonix Pharmaceuticals Holding Corp. (TNXP), Theravance, Switch Biotech, Pierre Fabre Mdicament, Merck Sharp and Dohme and Meiji Seika, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fibromyalgia Therapeutics Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fibromyalgia Therapeutics Drugs Market by Company
Eli Lilly
Pfizer
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Theravance
Switch Biotech
Pierre Fabre Mdicament
Merck Sharp and Dohme
Meiji Seika
Meda
Innovative Med Concepts
Forest Pharmaceuticals, Inc.
Daiichi Sankyo
Daiichi Sankyo
Boehringer Ingelheim GmbH
Actavis
Fibromyalgia Therapeutics Drugs Segment by Type
Cymbalta (Duloxetine)
Savella (Milnacipran)
Lyrica (Pregabalin)
Pancuronium
Others
Fibromyalgia Therapeutics Drugs Segment by Application
Hospital
Clinic
Others
Fibromyalgia Therapeutics Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibromyalgia Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fibromyalgia Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibromyalgia Therapeutics Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fibromyalgia Therapeutics Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fibromyalgia Therapeutics Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fibromyalgia Therapeutics Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cymbalta (Duloxetine)
- Savella (Milnacipran)
- Lyrica (Pregabalin)
- Pancuronium
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Eli Lilly
- Pfizer
- Zynerba Pharmaceuticals
- Tonix Pharmaceuticals Holding Corp. (TNXP)
- Theravance
- Switch Biotech
- Pierre Fabre Mdicament
- Merck Sharp and Dohme
- Meiji Seika
- Meda
- Innovative Med Concepts
- Forest Pharmaceuticals, Inc.
- Daiichi Sankyo
- Daiichi Sankyo
- Boehringer Ingelheim GmbH
- Actavis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fibromyalgia Therapeutics Drugs Market Size (2021-2032)
- 2.2.2 Global Fibromyalgia Therapeutics Drugs Sales (2021-2032)
- 2.2.3 Global Fibromyalgia Therapeutics Drugs Market Average Price (2021-2032)
- 2.3 Fibromyalgia Therapeutics Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cymbalta (Duloxetine)
- 2.3.3 Savella (Milnacipran)
- 2.3.4 Lyrica (Pregabalin)
- 2.3.5 Pancuronium
- 2.3.6 Others
- 2.4 Fibromyalgia Therapeutics Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fibromyalgia Therapeutics Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fibromyalgia Therapeutics Drugs Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Fibromyalgia Therapeutics Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Fibromyalgia Therapeutics Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Fibromyalgia Therapeutics Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fibromyalgia Therapeutics Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fibromyalgia Therapeutics Drugs, Product Type & Application
- 3.8 Global Manufacturers of Fibromyalgia Therapeutics Drugs, Established Date
- 3.9 Global Fibromyalgia Therapeutics Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly
- 4.1.1 Eli Lilly Company Information
- 4.1.2 Eli Lilly Business Overview
- 4.1.3 Eli Lilly Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.1.5 Eli Lilly Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Zynerba Pharmaceuticals
- 4.3.1 Zynerba Pharmaceuticals Company Information
- 4.3.2 Zynerba Pharmaceuticals Business Overview
- 4.3.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.3.5 Zynerba Pharmaceuticals Recent Developments
- 4.4 Tonix Pharmaceuticals Holding Corp. (TNXP)
- 4.4.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Information
- 4.4.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
- 4.4.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.4.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Developments
- 4.5 Theravance
- 4.5.1 Theravance Company Information
- 4.5.2 Theravance Business Overview
- 4.5.3 Theravance Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Theravance Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.5.5 Theravance Recent Developments
- 4.6 Switch Biotech
- 4.6.1 Switch Biotech Company Information
- 4.6.2 Switch Biotech Business Overview
- 4.6.3 Switch Biotech Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Switch Biotech Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.6.5 Switch Biotech Recent Developments
- 4.7 Pierre Fabre Mdicament
- 4.7.1 Pierre Fabre Mdicament Company Information
- 4.7.2 Pierre Fabre Mdicament Business Overview
- 4.7.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.7.5 Pierre Fabre Mdicament Recent Developments
- 4.8 Merck Sharp and Dohme
- 4.8.1 Merck Sharp and Dohme Company Information
- 4.8.2 Merck Sharp and Dohme Business Overview
- 4.8.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.8.5 Merck Sharp and Dohme Recent Developments
- 4.9 Meiji Seika
- 4.9.1 Meiji Seika Company Information
- 4.9.2 Meiji Seika Business Overview
- 4.9.3 Meiji Seika Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Meiji Seika Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.9.5 Meiji Seika Recent Developments
- 4.10 Meda
- 4.10.1 Meda Company Information
- 4.10.2 Meda Business Overview
- 4.10.3 Meda Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Meda Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.10.5 Meda Recent Developments
- 4.11 Innovative Med Concepts
- 4.11.1 Innovative Med Concepts Company Information
- 4.11.2 Innovative Med Concepts Business Overview
- 4.11.3 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.11.5 Innovative Med Concepts Recent Developments
- 4.12 Forest Pharmaceuticals, Inc.
- 4.12.1 Forest Pharmaceuticals, Inc. Company Information
- 4.12.2 Forest Pharmaceuticals, Inc. Business Overview
- 4.12.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.12.5 Forest Pharmaceuticals, Inc. Recent Developments
- 4.13 Daiichi Sankyo
- 4.13.1 Daiichi Sankyo Company Information
- 4.13.2 Daiichi Sankyo Business Overview
- 4.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.13.5 Daiichi Sankyo Recent Developments
- 4.14 Daiichi Sankyo
- 4.14.1 Daiichi Sankyo Company Information
- 4.14.2 Daiichi Sankyo Business Overview
- 4.14.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.14.5 Daiichi Sankyo Recent Developments
- 4.15 Boehringer Ingelheim GmbH
- 4.15.1 Boehringer Ingelheim GmbH Company Information
- 4.15.2 Boehringer Ingelheim GmbH Business Overview
- 4.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.15.5 Boehringer Ingelheim GmbH Recent Developments
- 4.16 Actavis
- 4.16.1 Actavis Company Information
- 4.16.2 Actavis Business Overview
- 4.16.3 Actavis Fibromyalgia Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Actavis Fibromyalgia Therapeutics Drugs Product Portfolio
- 4.16.5 Actavis Recent Developments
5 Global Fibromyalgia Therapeutics Drugs Market Scenario by Region
- 5.1 Global Fibromyalgia Therapeutics Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021-2032
- 5.2.1 Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021-2026
- 5.2.2 Global Fibromyalgia Therapeutics Drugs Sales by Region: 2027-2032
- 5.3 Global Fibromyalgia Therapeutics Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Fibromyalgia Therapeutics Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Fibromyalgia Therapeutics Drugs Revenue by Region: 2027-2032
- 5.4 North America Fibromyalgia Therapeutics Drugs Market Facts & Figures by Country
- 5.4.1 North America Fibromyalgia Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
- 5.4.3 North America Fibromyalgia Therapeutics Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Fibromyalgia Therapeutics Drugs Market Facts & Figures by Country
- 5.5.1 Europe Fibromyalgia Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Fibromyalgia Therapeutics Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Fibromyalgia Therapeutics Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fibromyalgia Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fibromyalgia Therapeutics Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fibromyalgia Therapeutics Drugs Market Facts & Figures by Country
- 5.7.1 South America Fibromyalgia Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
- 5.7.3 South America Fibromyalgia Therapeutics Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fibromyalgia Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fibromyalgia Therapeutics Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Fibromyalgia Therapeutics Drugs Sales by Type (2021-2032)
- 6.1.1 Global Fibromyalgia Therapeutics Drugs Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Fibromyalgia Therapeutics Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Fibromyalgia Therapeutics Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Fibromyalgia Therapeutics Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fibromyalgia Therapeutics Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Fibromyalgia Therapeutics Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fibromyalgia Therapeutics Drugs Sales by Application (2021-2032)
- 7.1.1 Global Fibromyalgia Therapeutics Drugs Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Fibromyalgia Therapeutics Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Fibromyalgia Therapeutics Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Fibromyalgia Therapeutics Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fibromyalgia Therapeutics Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Fibromyalgia Therapeutics Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fibromyalgia Therapeutics Drugs Value Chain Analysis
- 8.1.1 Fibromyalgia Therapeutics Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fibromyalgia Therapeutics Drugs Production Mode & Process
- 8.2 Fibromyalgia Therapeutics Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fibromyalgia Therapeutics Drugs Distributors
- 8.2.3 Fibromyalgia Therapeutics Drugs Customers
9 Global Fibromyalgia Therapeutics Drugs Analyzing Market Dynamics
- 9.1 Fibromyalgia Therapeutics Drugs Industry Trends
- 9.2 Fibromyalgia Therapeutics Drugs Industry Drivers
- 9.3 Fibromyalgia Therapeutics Drugs Industry Opportunities and Challenges
- 9.4 Fibromyalgia Therapeutics Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst